Syndax Pharmaceuticals (SNDX)
(Real Time Quote from BATS)
$20.95 USD
+0.14 (0.67%)
Updated Aug 28, 2024 11:08 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Syndax Pharmaceuticals, Inc. [SNDX]
Reports for Purchase
Showing records 1 - 20 ( 50 total )
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Data Update From Revumenib Combination Trials at EHA
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Syndax to Advance Into Phase 1b Portion of Proof-of-Concept Trial for Revumenib in r/r Metastatic MSS CRC
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Two PDUFA Action Dates on the Horizon in Less Than Five Months
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Presentation of Positive Pediatric Data From Pivotal AUGMENT-101 Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Complete Enrollment For AUGMENT-101 Pivotal Trial Cohort of Revumenib in r/r mNPM1 AML; Topline Data Expected 4Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA Grants Priority Review of NDA for Revumenib in r/r KMT2Ar Acute Leukemia
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Two Potential New Drug Launches in 2024; Reiterate Buy and $41 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Menin Inhibitors Carving Out a Niche in Leukemias: Rationale, Opportunities, and Candidates
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
NDA Submitted for Revumenib in R/R KMT2Ar Acute Leukemia and BLA Submitted for Axatilimab in cGVHD
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Model Update Following Raise; Lowering Price Target by $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Additional Data From the Pivotal AUGMENT-101 Trial at ASH 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Data Updates For Axatilimab and Revumenib at ASH 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for SNDX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Multiple Presentations Planned For ASH 2023 Annual Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Revumenib NDA Submission Planned Under FDA''s Real-Time Oncology Review Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Data From Pivotal AUGMENT-101 Trial of Revumenib in r/r KMT2Ar Acute Leukemia
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Two Potential Regulatory Filings Expected by Year-End; AUGMENT-101 Data Expected 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Primary Endpoint Reached Across All Dose Levels in Pivotal AGAVE-201 Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Syndax Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Top-Line Data From AUGMENT-101 Trial in KMT2Ar Acute Leukemia Patients Expected in 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E